Study of TQB2934 for multiple myeloma that has come back or not improved
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new treatment called TQB2934 for people with multiple myeloma that has returned or hasn't gotten better after treatment. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have multiple myeloma that has come back or not responded to at least one previous treatment.
- You must be able to take care of yourself (up to bedridden for less than half the day).
- You must have a life expectancy of more than 3 months.
- You must agree to use effective birth control during the study and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial is testing a new drug called QL2109 combined with Darzalex Faspro (daratumumab and hyaluronidase) for people with multiple myeloma that has returned or not responded to earlier treatments. The goal is to see if this combination can better control the cancer compared to standard options.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This study tests an experimental drug called LBL-034 for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.